Why and how the old neuroleptic thioridazine cures the XDR-TB patient

Leonard Amaral, Joseph Molnar

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

This mini-review provides the entire experimental history of the development of the old neuroleptic thioridazine (TZ) for therapy of antibiotic resistant pulmonary tuberculosis infections. TZ is effective when used in combination with antibiotics to which the initial Mycobacterium tuberculosis was resistant. Under proper cardiac evaluation procedures, the use of TZ is safe and does not produce known cardiopathy such as prolongation of QT interval. Because TZ is cheap, it should be considered for therapy of XDR and TDR-Mtb patients in economically disadvantaged countries.

Original languageEnglish
Pages (from-to)1021-1031
Number of pages11
JournalPharmaceuticals
Volume5
Issue number9
DOIs
Publication statusPublished - Jul 17 2012

    Fingerprint

Keywords

  • Cures the human of an XDR-TB infection
  • Cures the mouse of MDR-Mtb infections
  • Enhances killing of intracellular Mtb
  • Ex vivo activity
  • In vitro activity
  • Inhibitor of efflux pumps
  • Mechanisms of action
  • Pulmonary tuberculosis
  • TDR-TB
  • Thioridazine
  • XDR-TB

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this